Ixico plc
IXICO plc is an AIM-quoted, UK-domiciled imaging Contract Research Organisation (iCRO) and AI-driven biomarker analytics company serving the global biopharmaceutical industry. Its proprietary IXI platform analyses MRI/PET/SPECT neuroimaging data to support clinical trials and drug development in neurodegenerative diseases such as Alzheimer's, Huntington's and Parkinson's. The Group also supports diagnostic validation (e.g. blood-based biomarkers) and post-market surveillance beyond core clinical-trial imaging services.
FY2025 in sixty seconds
year to 30 Sept 2025 · approved 8 Dec 2025 · 86 pages · Companies House
IXICO plc analyses brain scans for drug companies running clinical trials in diseases such as Alzheimer's and Huntington's. In the year to 30 September 2025 revenue rose to £6.5m from £5.8m, and the loss after tax narrowed to £1.7m from £2.0m. The loss from day-to-day operations, before tax, widened to £2.6m from £2.2m.
The report puts the growth down to new contracts and extensions of existing ones, while the company invested in its operations in the US and in its technology. The two measures of loss moved in opposite directions partly because a research and development tax credit is now counted in the tax line rather than as other income.
Cash at the year end was £3.5m, after £3.7m was raised from shareholders by issuing new shares. There are no borrowings and no dividend. Management says it will seek further double-digit revenue growth in 2026. The auditors raised no doubt about the company's ability to keep trading, but the report notes that it is loss-making and uses up cash, and that clients can end trials early.
New contracts with new and existing clients across therapeutic areas, clinical phases and geographies
Positive commercial momentum is the result of four key drivers: i. New contracts... ii. Scope extensions... iii. Expansion into new industry verticals... iv. Continual scientific innovation
page 8Revenue mix shift between early-phase (I/II) and later-phase trials
approximately 55% of the Group's revenues have been from phase I and phase II clinical trials (2024: 60%), which tend to be lower margin than later phase trials
page 16The ambition is to grow long term revenues towards £20 million+ with a target of reaching £10 million revenues in the medium term.
page 9The Board of Directors does not recommend the payment of a dividend. No authority to buy back the Company's ordinary shares has been sought.
page 3911 years on one page · FY2015–FY2025
| Line | FY2015locked | FY2016locked | FY2017locked | FY2018locked | FY2019locked | FY2020locked | FY2021locked | FY2022locked | FY202309/23 | FY202409/24 | FY202509/25 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | |||||||||||
| Operating profit | |||||||||||
| Profit for the year | |||||||||||
| Basic EPS | |||||||||||
| Free cash flow | |||||||||||
| Net debt (negative = net cash) | |||||||||||
| Shares in issue | |||||||||||
| Operating margin | |||||||||||
| Return on capital employed |
GBP millions, negatives in brackets. Per-share lines in pence. Share counts in millions. Margins and returns as percentages, calculated from the filed figures. later is what a following report restated the figure to; vs is a second reading that disagrees. The figure shown is the one the original filing printed, and both readings are kept. Click any figure: opens the report page it was read from, highlighted; shows how it was calculated.
36 figures restated in a later report
Every figure is read again from the following year’s report: 285 confirmed, 11 differ, 36 restated.
No figure has been restated: every figure a later report printed again, it printed the same.
36 more figures were restated in FY2015 to FY2022, which a free account opens.